Volume 2, Issue 5
Editorialp. 357
How can we reduce racial/ethnic disparities in diabetes medication adherence?
Author(s): Chandra Y Osborn
Editorialp. 361
How do genetic and environmental factors interact in diabetic kidney disease?
Author(s): Farook Thameem, Hanna E Abboud, Sharon G Adler
Editorialp. 365
The Warsaw School of Insulin Pump Therapy: achievements and widespread implications for the diabetes clinic
Author(s): Ewa Pankowska
News and Viewsp. 369
News
News and Viewsp. 373
Our experts highlight the most important research articles across the spectrum of topics relevant to the field of diabetes management
Author(s): Prasad Bichu, Preethi Yerram, Adam Whaley-Connell & Charlie Dong
Dissecting gene�environment contributions to Type 2 diabetes
Author(s): Braxton D Mitchell, Robert L Hanson
Research Articlep. 379
Transition in Type 1 diabetes mellitus from a tertiary pediatric center: what are we doing before they walk out the door?
Author(s): Mary White, Michele A O\'Connell & Fergus J Cameron
Research Articlep. 385
Factors associated with participation in a diabetes prevention program in Austria: a prospective cohort study
Author(s): Yvonne Teuschl, Karl Matz, Alexandra Dachenhausen,Jaakko Tuomilehto & Michael Brainin
Review Articlep. 395
Doctor, stop needling me: an update on alternative routes of insulin administration
Author(s): Erin D Roe, Jason S Woo & Philip Raskin
Review Articlep. 405
In search of improved glucose control: helping the patient decide between insulin injections and infusion pump therapy
Author(s): Erin D Roe, Jason S Woo & Philip Raskin
Review Articlep. 419
Components and validity of risk scores for screening for Type 2 diabetes mellitus
Author(s): Chung T Nguyen, Andy H Lee & Colin W Binns
Review Articlep. 427
Biomarkers for evaluating renal function decline in diabetes: where are we now?
Author(s): Janet K Snell-Bergeon
Review Articlep. 439
Molecular action and pharmacogenetics of metformin: current understanding of an old drug
Author(s): Graham Rena, Ewan R Pearson& Kei Sakamoto
Review Articlep. 453
Vildagliptin: a DPP-4 inhibitor for the treatment of Type 2 diabetes
Author(s): Bo Ahren
Special Issue Articlep. 1
Pioglitazone ODTs offer potential to improve treatment compliance in Type 2 diabetes mellitus
Author(s): Kohei Kaku
Special Issue Articlep. 3
Bioequivalence evaluation of pioglitazone orally disintegrating tablet formulation
Author(s): Shinzo Hiroi, Kumi Matsuno, Masashi Hirayama, Takaki Hayakawa,Norihito Yoshioka & Koji Kawakami
Special Issue Articlep. 13
Evaluation of the bioequivalence of a fixed-dose combination tablet of pioglitazone-metformin versus commercial tablets in healthy Japanese male volunteers
Author(s): Shinzo Hiroi, Kumi Matsuno, Masashi Hirayama, Takaki Hayakawa,Norihito Yoshioka & Koji Kawakami
Special Issue Articlep. 21
Bioequivalence of a pioglitazone-glimepiride combination tablet versus coadministered single-dose pioglitazone and glimepiride in healthy Japanese subjects
Author(s): Shinzo Hiroi, Kumi Matsuno, Masashi Hirayama, Kenji Kuriyama & Koji Kawakami
